A2A receptors in neuroprotection of dopaminergic neurons.
Pedata
Felicita
F
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy. felicita.pedata@unifi.it
Pugliese
Anna Maria
AM
Melani
Alessia
A
Gianfriddo
Marco
M
D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D002110:Caffeine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D011687:Purines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D043705:Receptor, Adenosine A2A / Q000378:metabolism*; D012737:Sex Factors; D014230:Triazoles / Q000627:therapeutic use
C098657:5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; D058917:Adenosine A2 Receptor Antagonists; D004791:Enzyme Inhibitors; D018696:Neuroprotective Agents; D011687:Purines; D011743:Pyrimidines; D043705:Receptor, Adenosine A2A; D014230:Triazoles; C111599:istradefylline; D002110:Caffeine; D004298:Dopamine